Pulmonary Drugs Market Report Scope & Overview:

The Pulmonary Drugs Market was valued at USD 17.80 Billion in 2025 and is expected to reach USD 32.48 Billion by 2035, growing at a CAGR of 6.20% from 2026-2035.

Pulmonary drugs are medicines formulated to treat chronic and acute respiratory conditions, spanning established inhaled bronchodilators and corticosteroids alongside newer injectable monoclonal antibodies targeting specific inflammatory pathways in severe asthma and COPD. Demand continues to expand as rising air pollution, smoking-related lung damage, and aging populations increase the prevalence of chronic respiratory disease worldwide. Biologic therapies are reshaping treatment for patients whose disease remains poorly controlled on conventional inhaled regimens, while generic drugmakers intensify competition as patents on several inhaler combination products lapse. Growing clinical focus on under-served indications such as idiopathic pulmonary fibrosis and non-cystic fibrosis bronchiectasis is also widening the addressable patient population for pharmaceutical developers.

⮞In May 2026, Boehringer Ingelheim received Japanese regulatory approval for JASCAYD (nerandomilast) for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The oral PDE4B inhibitor introduces a new treatment option targeting pulmonary fibrosis through antifibrotic and immunomodulatory effects.

U.S. Pulmonary Drugs Market Outlook

The U.S. Pulmonary Drugs Market was valued at USD 5.82 Billion in 2025 and is expected to reach USD 10.42 Billion by 2035, growing at a CAGR of 6.00% from 2026-2035.

Demand across the United States is shaped by a large population living with asthma and COPD, alongside insurers that increasingly steer patients toward lower-cost generic inhalers once reference products lose exclusivity. Rapid first-to-file generic approvals for inhalation aerosol products are compressing prices within months of a patent expiry, while originator companies concentrate clinical and regulatory resources on bringing novel biologic and small-molecule therapies to market. This combination of an established generics pipeline and fast-moving innovator competition gives the country an early-adopter position relative to most other national markets.

⮞In December, 2025, Amneal Pharmaceuticals received US FDA approval for its albuterol sulfate inhalation aerosol, a generic version of Teva Respiratory's ProAir HFA.

By Drug Class, Combination Drugs Dominates the Pulmonary Drugs Market and Monoclonal Antibodies Grows Fastest

Combination drugs hold the dominant drug-class share in 2025, reflecting prescriber preference for pairing a bronchodilator with an inhaled corticosteroid or a second bronchodilator in a single device rather than managing separate component therapies. This simplification improves patient adherence for chronic daily maintenance treatment and has driven steady replacement of older single-agent inhalers across both asthma and COPD care pathways. Established combination products from major originator companies continue to anchor prescribing volume even as generic versions enter most major markets, reinforcing the drug class's position as the default starting point for most long-term maintenance treatment decisions.

Monoclonal antibodies are the fastest-growing drug class, as biologic therapies targeting specific inflammatory pathways increasingly address patients who need more than inhaled therapy to control their disease. There is growing clinical evidence for the use of biologics in both severe asthma and COPD, increasing the eligible patient population beyond the most severe cases for which biologics were first approved. This evidence is also encouraging originator companies to pursue label expansions into related respiratory diseases with overlapping inflammatory pathways.

⮞In September 2026, AstraZeneca reported that the U.S. FDA had accepted, under a priority review voucher, its biologics license application for tozorakimab for chronic obstructive pulmonary disease, with a regulatory decision expected in the first quarter of 2027.

By Indication, Asthma Dominates the Pulmonary Drugs Market and Allergic Rhinitis Grows Fastest

Asthma accounts for the dominant indication share in 2025, consistent with its position as the most prevalent chronic respiratory condition requiring long-term maintenance pharmacotherapy across pediatric and adult patients worldwide. The scale of diagnosed asthma cases, combined with an expanding menu of inhaled and biologic options across disease severity, gives asthma a scale advantage over indications such as pulmonary arterial hypertension. Treated populations in those indications remain comparatively small and specialized, which limits the commercial scale most drug developers can realistically pursue.

Allergic rhinitis is the fastest-growing indication, as rising global pollen exposure and urban air pollution expand the diagnosed patient population beyond those managed solely with over-the-counter antihistamines. Physicians are increasingly prescribing dedicated intranasal and combination pharmacotherapy for patients whose symptoms disrupt sleep and daily activity. This shift is reinforced by growing recognition of the condition's link to asthma exacerbation risk in patients who have both conditions. As a result, allergy and respiratory specialists are coordinating treatment more closely across primary and specialist care, particularly in regions where seasonal pollen counts are rising.

By Route of Administration, Inhaled Dominates the Pulmonary Drugs Market and Intranasal Grows Fastest

Inhaled therapy holds the dominant route-of-administration share in 2025, reflecting its established position as the preferred delivery method for depositing medication directly into the airways while minimizing systemic exposure relative to oral or injectable alternatives. Decades of device innovation across metered-dose inhalers, dry powder inhalers, and nebulized solutions have made inhaled therapy the default choice for both acute symptom relief and chronic maintenance treatment across nearly every major respiratory indication treated today, giving device manufacturers a durable installed base of prescriber familiarity to build upon.

Intranasal administration is the fastest-growing route, as rising allergic rhinitis diagnoses and growing patient preference for localized, rapid-acting therapy support wider adoption of nasal sprays over oral antihistamines alone. Manufacturers are increasingly developing intranasal corticosteroid and combination formulations that offer faster symptom relief. Expanding retail availability is broadening patient access beyond prescription-only channels in several major markets, particularly among patients seeking convenient self-administered treatment over longer-acting oral alternatives that can take days to reach full effect.

⮞In April, 2026, Cipla received final USFDA approval for Albuterol Sulfate Inhalation Aerosol, the first AB-rated generic therapeutic equivalent of GSK's Ventolin HFA.

By Distribution Channel, Retail Pharmacies Dominates the Pulmonary Drugs Market and Other Channels Grows Fastest

Retail pharmacies held the dominant distribution-channel share in 2025, as they are the most convenient point of purchase for patients refilling long-term maintenance inhaler prescriptions each month. Chain and independent retail pharmacies have established relationships with insurers that allow reimbursement of chronic respiratory therapy. Their physical presence in urban and suburban communities makes them the de facto channel for most patients filling pulmonary drug prescriptions. Decades of patient familiarity with routine pharmacy counseling and refill reminders continue to reinforce this pattern.

Other distribution channels, including online and specialty pharmacy networks, are the fastest-growing category, as patients managing chronic, stable prescriptions increasingly value home delivery and specialty pharmacy support for complex biologic therapies requiring cold-chain handling. Manufacturers of injectable biologics are increasingly routing newly approved therapies through specialty pharmacy networks that can manage patient support programs alongside drug delivery. This shortens the path between regulatory approval and patient access for complex new treatments. These networks also coordinate prior-authorization support for patients navigating higher-cost biologic regimens.

Regional Analysis

North America Pulmonary Drugs Market Insights

North America is the largest regional market, with an estimated 38.00% share in 2025, anchored by the United States' large diagnosed respiratory patient population and the concentration of originator pharmaceutical companies advancing novel biologic candidates through late-stage trials. Established insurance and pharmacy benefit management infrastructure supports broad patient access to both generic and newly approved branded therapies, while the region's regulatory pathway continues to give companies a comparatively fast route to market relative to most other regions, reinforcing its position as the first launch market for most new pulmonary drug approvals.

Canada contributes a smaller but steady share of regional demand, with provincial drug plans gradually expanding coverage for newer biologic therapies as supporting clinical evidence accumulates across formulary review cycles. Continued patent expirations on combination inhaler products are widening access to lower-cost therapy across the region, while leading pharmaceutical companies headquartered in the United States continue to treat the United States as the first filing market for most new pulmonary therapies, giving the broader region comparatively early access.

Asia Pacific Pulmonary Drugs Market Insights

Asia Pacific recorded the fastest regional growth, with a CAGR of approximately 6.80% from 2026-2035, driven by rising air pollution exposure, expanding generic drug manufacturing capacity, and growing government investment in chronic respiratory disease treatment across India and China. India's large base of generic drugmakers continues to file early for first-to-market approvals on newly off-patent inhalation products, widening access to lower-cost therapy faster than in most established markets, aided by manufacturing scale built up across decades of serving both local and export generics demand.

China's growing base of local healthcare infrastructure investment is widening access to both generic and newer branded respiratory therapies, while Japan's established pharmaceutical infrastructure and South Korea's growing clinical trial capacity are both contributing to regional demand. Expanding private hospital networks across the broader region are gradually introducing newer biologic drug classes for patients able to afford advanced therapy, narrowing the gap with longer-established Western markets as local research capability continues to mature and regional regulatory agencies streamline review timelines for imported therapies.

⮞In May, 2026, Lupin received tentative US FDA approval for its generic revefenacin inhalation solution for COPD, bioequivalent to Mylan's Yupelri Inhalation Solution.

Europe Pulmonary Drugs Market Insights

Europe is the second-largest regional market, with an estimated 27.00% share in 2025, supported by Germany's large diagnosed patient base and the region's generally coordinated health technology assessment processes for new biologic and inhaled therapies. Several national health systems across the region maintain extensive reimbursement coverage for established generic drug classes, giving manufacturers an incentive to prioritize European regulatory filings alongside their primary submissions in the United States ahead of broader national pricing negotiations that can take considerable time to conclude across multiple member states.

The United Kingdom and France both maintain substantial prescribing volumes for established inhaled therapies and are gradually expanding guideline-driven access to newer biologic classes as supporting clinical evidence accumulates across national assessment bodies that can take several years to complete a full formulary review. Regional pharmaceutical companies continue to invest in next-generation respiratory candidate development, an area where several European life sciences companies maintain long-standing research expertise built up over decades of continuous pulmonary disease investment and close academic collaboration across major teaching hospitals.

⮞In the first quarter of 2026, the European Commission approved GSK's Nucala (mepolizumab) as an add-on treatment for COPD with an eosinophilic phenotype, extending the biologic's approved use in Europe.

MEA & Latin America Pulmonary Drugs Market Insights

The Middle East and Africa is a smaller but steadily growing market for pulmonary drugs, with an estimated 6.00% share in 2025, led by Saudi Arabia and the United Arab Emirates as both countries invest in expanding chronic-disease treatment access amid rising respiratory disease prevalence tied to regional air quality and climate conditions. South Africa's more established generics manufacturing base continues to broaden locally registered treatment options, though access across the wider region remains uneven outside major urban health systems.

Latin America represented a smaller 5.00% share in 2025, with Brazil as the region's largest national market given its sizable diagnosed patient population and growing local generics sector. Mexico's expanding public and private healthcare networks are gradually widening access to newer biologic drug classes for patients with private coverage, while broader regional adoption continues to be shaped by reimbursement limitations and the comparatively higher cost of newer branded treatments relative to established generic alternatives.

Market Dynamics

Growth Drivers: Rising respiratory disease burden and expanding biologic approvals sustain demand

Rising global prevalence of asthma and COPD, driven by air pollution, smoking-related lung damage, and aging populations, is a primary driver of sustained demand for pulmonary pharmacotherapy across both developed and emerging markets. Physicians continue to escalate treatment from inhaled therapy toward biologic options for patients whose symptoms persist despite inhaled treatment, giving the broader drug class a durable position in standard respiratory care pathways across nearly every national treatment guideline currently in use by prescribing physicians worldwide, reinforcing steady prescription volume growth across most age groups.

A second driver is expanding regulatory approval of novel therapies for specific respiratory indications, including biologics for severe asthma and new treatments for under-served conditions such as idiopathic pulmonary fibrosis. Regulatory approvals extending drug indications into broader or younger patient populations are widening the addressable base for originator companies, reinforcing demand for premium branded therapy even as generic competition intensifies across established inhaled drug classes, particularly across markets with expanding specialty reimbursement coverage and growing physician familiarity with biologic treatment protocols for severe disease.

Restraints: Pipeline trial setbacks and entrenched inhaled therapy preference constrain growth

Mixed or unsuccessful clinical trial outcomes among biologic pipeline candidates remain a meaningful restraint, as a disappointing Phase 3 readout can delay a promising program's advancement toward market and reduce investor confidence in similarly structured candidates under development elsewhere. Such setbacks reinforce caution among regulators and prescribing physicians evaluating newer biologic entrants, slowing the pace at which innovative therapies can displace established inhaled treatment pathways across major markets and discouraging smaller developers from committing capital to similarly structured programs without stronger early efficacy signals in hand.

A second restraint is the entrenched clinical and cost preference for established inhaled generic therapy among patients with mild to moderate disease, a segment where newer biologic candidates have not yet demonstrated a clear advantage sufficient to justify their substantially higher treatment cost. This preference limits how quickly newer drug classes can capture volume from inhaled incumbents, particularly among cost-conscious health systems and payers managing broad chronic-disease treatment budgets across both public and private insurance programs in most major markets.

Opportunities: Pipeline expansion through acquisition and under-served indications widen demand

Continued pharmaceutical company investment in acquiring clinical-stage respiratory biotechnology developers represents a significant opportunity, as larger companies seek to replace revenue from aging franchises by securing differentiated late-stage biologic assets targeting asthma and related inflammatory conditions. Companies completing such acquisitions are positioned to bring next-generation therapies to market faster than building comparable pipeline depth through internal research alone, while adding depth that strengthens their position against competitors pursuing similar inflammatory disease targets across adjacent indications, and such deals often command substantial premiums reflecting the scarcity of differentiated late-stage respiratory assets available for acquisition.

A second opportunity lies in expanding treatment of previously under-served respiratory indications, including non-cystic fibrosis bronchiectasis and idiopathic pulmonary fibrosis, where few approved therapies have historically existed. Companies securing approval for first-in-category treatments in these indications stand to capture an initially uncontested patient population before competitors can bring comparable therapies through clinical development, establishing reference treatment standards that later entrants will need to match once broader clinical adoption accelerates across both specialist and general pulmonology practice settings worldwide, particularly as patient advocacy groups raise awareness of diagnostic pathways for these previously overlooked conditions.

Pulmonary Drugs Market Key Players

• GSK plc

• AstraZeneca plc

• Boehringer Ingelheim International GmbH

• Novartis AG

• F. Hoffmann-La Roche Ltd.

• Sanofi S.A.

• Regeneron Pharmaceuticals, Inc.

• Merck & Co., Inc.

• Vertex Pharmaceuticals Incorporated

• Cipla Limited

• Lupin Limited

• Grifols, S.A.

• Teva Pharmaceutical Industries Ltd.

• Pfizer Inc.

• Chiesi Farmaceutici S.p.A.

• Amgen Inc.

• Amneal Pharmaceuticals, Inc.

• Glenmark Pharmaceuticals Ltd.

• Viatris Inc.

Pulmonary Drugs Market Report Scope: